Oct 21 (Reuters) - AstraZeneca said on Wednesday the US Food and Drug Administration granted accelerated approval for its treatment for adults with immunoglobulin A nephropathy, a rare kidney disease ...
AstraZeneca PLC (NYSE:AZN) is lagging the broader market this year so far, with shares declining by over 8%. The ...
Oct 20 () - Amgen and AstraZeneca said on Tuesday their asthma drug helped reduce swallowing difficulties and achieved ...
AstraZeneca will tap AI-focused insitro to find new targets for metabolic dysfunction-associated steatohepatitis and ...
Jefferies, the investment bank, estimates a 59% probability that AstraZeneca PLC (LSE:AZN, NYSE:AZN)’s zibotentan succeeds in ...
AstraZeneca partners with insitro on an AI drug discovery deal worth up to $1.86 billion targeting fatty liver disease and ...
Several Oncology Catalysts, One Earnings Question AstraZeneca PLC (NYSE:AZN) enters the3-27 European Society for Medical ...
In 2025, AstraZeneca continues to impress me with the strong performances of its oncology, cardiovascular, and rare disease franchises. So, revenue from Enhertu, which is a highly effective ...
Pascal Soriot spoke exclusively with CNBC from the site of AstraZeneca's new $1 billion R&D facility in Kendall Square in Cambridge, Massachusetts.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results